In biology textbooks and beyond, the human genome and DNA therein typically are taught in only one dimension. While it can be ...

As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds—ticks.

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma.

Discover more about emerging oncolytic cancer therapies in development @ Oncolytic Virus Cancer Clinical Trials and FDA Approvals Table of Contents 1. Oncolytic Virus Therapies Market Key Insights 2.

What is the growth forecast for oncolytic virus therapy market? Answer: The global oncolytic virus therapy market is expected to grow with a CAGR of 15.8% from 2024 to 2030. Q2.

VCN-01 is an oncolytic adenovirus intended to selectively replicate within tumor cells and degrade the tumor stroma, breaking down the physical and immunosuppressive barrier to cancer treatment.

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy.

ONCOTECH has been developed to physically attach oncolytic adenoviruses to T cell surfaces through the interaction of antigens and receptors.

Johanna Kaufmann, PhD, discusses promising preclinical findings on first-in-class oncolytic viral therapy in breast cancer treatment.

Oncolytic viruses have emerged as a promising option. Oncolytic viruses selectively replicate within tumor cells, destroying them and stimulating the immune system for an enhanced anticancer response.